“DISTINGUISHED EXPERT ON SYMBIOTIC BACTERIA PROF. ROLF LOOD JOINS S-BIOMEDIC’S SCIENTIFIC ADVISORY BOARD”
Beerse, Belgium, September 12th, 2019:
Prof. Rolf Lood is an associate professor of Experimental Infection Medicine at Lund University, Sweden, and vice president of Research and Development at Genovis.
S-Biomedic NV, a Belgium-based life science company, is exploring the therapeutic and cosmetic potential of the skin microbiome for skin health and dermatology applications.
Prof. Rolf Lood, an established expert on the beneficial and detrimental aspects of microbes, joins S-Biomedic’s scientific advisory board, consisting of a group of academic and industry experts in the field of microbiome research.
“I am pleased to join the advisory team of one of Europe’s leading biotech start-ups”, said Prof. Lood. “I hope to contribute with my academic and industrial expertise, which seem to be highly relevant to the research activities of S-Biomedic. At the same time, this assignment is really inspiring given the disruptive science of the skin microbiome modulation.”
As an associate professor of Experimental Infection Medicine at Lund University, Sweden, one of the main research areas of Prof. Lood is benevolent bacteria. Prof. Lood is also heading a team of researchers at Genovis AB, developing novel enzymes that target immunoglobulins.
Other members of S-Biomedic’s scientific advisory board are:
Prof. Harald Gollnick, former director and head of the Department of Dermatology and Venereology at Otto-von-Guericke University Magdeburg in Germany. Prof. Gollnick is a distinguished expert in the field of dermatological research and was past president and honorary member of the UEMS, a driving force in implementing a harmonised European curriculum for residents and undergraduates in the speciality of Dermatology and Venerology.
Prof. Holger Brueggemann, associate professor of the Department of Biomedicine at Aarhus University, Denmark. Prof. Brueggemann is an international expert on Cutibacterium acnes and led the research team that described the first whole genome sequence of C. acnes.
Dr Lieve Declerc, founder of Skin-DLite Consulting and former vice president of Basic Science Research Europe & Asia of Estee Lauder. Dr Declerc has more than 25 years of experience in cosmetic R&D and in implementing innovative technologies into new products.
Prof. Marc Güell, scientific director and non-executive scientific director of S-Biomedic, and tenure track professor at Pompeu Fabra University, Barcelona. Prof. Güell is a serial entrepreneur and leading researcher in the field of synthetic biology.
“Prof. Lood‘s insights into the positive symbiosis between skin bacteria and the host will be helpful as we continue to build our platform and grow the company following our Series A financing late last year”, said Veronika Oudova, CEO of S-Biomedic. “Together with the other distinguished members of our Scientific Advisory Board, Prof. Lood will help us to guide our R&D programs to success.”
About S-Biomedic
S-Biomedic is a Belgium-based life-science company working with live bacteria to develop treatments and products for skin disorders. S-Biomedic has developed a method to directly modulate the skin microbiome, with applications in dermatology and the cosmetic industry. The skin microbiome, a habitat of billions of good and bad bacteria, contributes to clinical conditions ranging from acne, eczema and rosacea, to ageing. Currently, S-Biomedic has developed its first active ingredient targeting acne and is further expanding its range of additional cosmetic and therapeutic applications to include solutions for skin ageing and dandruff. More information on www.sbiomedic.com.
For more information please contact:
S-Biomedic
Veronika Oudova, CEO
Veronika.oudova@sbiomedic.com
Phone +32 477269940
Download the press release below.